Breathing support options for adults with Guillain-Barré respiratory failure
Official title: Prospective, Randomized, Controlled, Open-Label Single-Center Trial Comparing High-Velocity Nasal Insufflation (HVNI) Versus Non-Invasive Ventilation (NIV) for Acute Respiratory Failure in Guillain-Barré Syndrome
Run by Assiut University · NCT06996509 · Data updated 2026-11-12
This will test whether high-velocity nasal cannula or bi-level noninvasive ventilation works better for adults with Guillain-Barré syndrome who have severe breathing problems.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 80 (estimated) |
| Sponsor | Assiut University Academic / other |
| Locations | 2 sites (Asyut, Assuit and 1 other locations) |
| Status | Recruiting |
| Started | August 1, 2025 |
| Main results expected | December 1, 2026 |
| Study ends | February 1, 2027 |
| Registry record updated | September 22, 2026 |
| Trial ID | NCT06996509 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults (≥18) with Guillain-Barré syndrome who developed moderate acute respiratory failure within 7 days, meet specified breathing and neurologic score thresholds (e.g., VC 15–20 mL/kg, Hughes grade 3–4, EGRIS 1–3), and are hemodynamically stable with intact airway reflexes.
✕Probably not a fit
Patients who already need immediate invasive ventilation, have severe bulbar dysfunction, chronic respiratory disease, or contraindications to HVNC/NIV are unlikely to benefit from participating.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional study will enroll 70 adults with Guillain-Barré syndrome and moderate acute respiratory failure to compare high-velocity nasal cannula (HVNC) and bi-level noninvasive ventilation (NIV). Participants will be assigned to receive either HVNC (heated, humidified flow 35–60 L/min) or bi-level NIV (IPAP 10–16 cmH2O and EPAP 5–8 cmH2O) and followed for 30 days. The primary outcome is liberation from non-invasive support without need for invasive mechanical ventilation by Day 30, with secondary outcomes including time to discontinuation, patient comfort, ICU and hospital length of stay, ventilator-free days, and 30-day mortality. Entry criteria focus on adults with recent respiratory symptom onset and specified respiratory function and neurologic scores, while those with chronic lung disease, severe bulbar dysfunction, or immediate need for intubation are excluded.
Why it matters
Potential benefit: If successful, the trial could identify a more comfortable respiratory support method that reduces the need for invasive ventilation and shortens ICU and hospital stays.
How similar studies have gone: Noninvasive ventilation is an established treatment in other causes of respiratory failure and high-flow nasal therapies have shown benefits in some populations, but direct comparisons in Guillain-Barré syndrome remain relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years * GBS per Brighton criteria (clinical ± cerebrospinal fluid (CSF)/electrodiagnostics) * Moderate acute respiratory failure (vital capacity (VC) 15-20 mL/kg and/or arterial partial pressure of carbon dioxide (PaCO₂) \> 45 mmHg or arterial partial pressure of oxygen (PaO₂) \< 70 mmHg on room air (RA) and/or respiratory rate (RR) \> 24 /min) * Hughes Grade 3-4, The Erasmus Guillain-Barré Syndrome Respiratory Insufficiency Score (EGRIS) 1-3, Medical Research Council (MRC) sum score 20-40 * Glasgow Coma Scale (GCS) ≥ 13, intact cough/gag, stable hemodynamics * Onset of respiratory symptoms ≤ 7 days Exclusion Criteria: * Chronic respiratory disease (COPD, interstitial lung diseases (ILD), persistent asthma) * Immediate need for invasive ventilation (VC \< 10 mL/kg, unresponsive severe gas-exchange derangement) * Severe bulbar dysfunction or prior intubation for the current illness * Contraindications to HVNC/NIV (facial trauma, untreated pneumothorax, agitation, vomiting) * Pregnancy * Severe comorbidity limiting prognosis. * Declined consent
Where it's running
-
Assuit Univeristy
Asyut, Assuit, Egypt Recruiting -
Faculty of Medicine - Assiut University Hospitals - Assiut University - Egypt
Asyut, Egypt Recruiting
Study contacts
- Principal investigator: Ahmad M. Shaddad, MD — Assiut University
- Study coordinator: Ahmad M. Shaddad, MD
- Email: shaddad_ahmad@yahoo.com
- Phone: +201111171930
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Tanruprubart (ANX005) treatment for Guillain-Barré syndrome (FORWARD)
This study will test tanruprubart (ANX005) in adults and children with recent-onset Guillain-Barré syndrome to see if it is safe, how the drug behaves in the body, and whether it helps recovery.
-
Comparing early and late tracheostomy in patients with Guillain-Barre syndrome
This study is testing if doing a tracheostomy sooner rather than later can help patients with Guillain-Barre syndrome who need breathing support recover faster and have better outcomes.
-
Identifying biomarkers for autoimmune diseases affecting the nervous system
This study is trying to find specific markers in the blood of people with autoimmune diseases affecting the nervous system, like Multiple Sclerosis, to help with early diagnosis and better treatment options.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.